Evaxion Biotech Announces Pricing of $15 Million Public Offering
Evaxion announced the pricing of a public offering of an aggregate of 3,750,000 of its American Depositary Shares (“ADSs”) (or pre-funded warrants in lieu thereof) and warrants to purchase up to 3,750,000 ADSs at a combined public offering price of $4.00 per ADS (or pre-funded warrant in lieu thereof) and accompanying warrant.
Evaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against Gonorrhea
Evaxion announced a collaboration with Afrigen Biologics (Afrigen).
Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company
Evaxion announced the initiation of a novel pipeline program, EVX-B3, an AI-designed vaccine candidate against an undisclosed bacterial pathogen.
Targeting neoantigens to APC- surface molecules improves the immunogenicity and anti-tumor efficacy of a DNA cancer vaccine
In this study, we demonstrate how the addition of an antigen-presenting cell (APC) binding molecule to DNA-encoded cancer neoepitopes improves neoepitope-specific T-cell responses and the anti-tumor efficacy of plasmid DNA vaccines.
Revolutionizing Vaccine Discovery: New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine Development
Evaxion has achieved a groundbreaking milestone in vaccine discovery with the validation of its AI-powered vaccine discovery platform, EDEN.
Evaxion announces Executive Management Changes to strengthen the AI-strategy
Evaxion has hired a new Chief Executive Officer (“CEO”) to accelerate the strategic development and execution of the vast business opportunities at hand after having matured the Company’s AI platforms over the past 15 years.
Learn more about Evaxion
We're advancing a robust product pipeline through our state-of-the-art platforms in cancer and infectious disease. Our focus is on drug discovery and early drug development, with an eye towards a future that reimagines the way cancer and infectious diseases are treated - and even cured.
We are 50 hearts and minds working closely together in a fully integrated AI and research facility in Hørsholm just north of Copenhagen. As pioneers and leaders in AI-Immunology powered vaccines, we seek, employ and develop the best scientific minds and extraordinarily skilled people.
Subscribe to our Newsletter
Be the first to know about news, milestones and events at Evaxion by subscribing to our newsletter. You'll only hear from us when it's important, and can unsubscribe at any time.